Professor Gus Gazzard: SLT (Selective Laser Trabeculoplasty) Trial
Prof. Gazzard is the Chief Investigator of the LiGHT study (Laser in Glaucoma and Ocular Hypertension), a large multicentre £1.8m NIHR-HTA funded trial of Selective Laser Trabeculoplasty.
The aim of this study is to compare the quality of life of patients who start treatment with medicines (eye-drops) to those who are first treated with selective laser trabeculoplasty (SLT) and then receive drops later as necessary. Newly diagnosed subjects, with no previous treatment for glaucoma who attend an outpatient clinic at Moorfields Eye Hospital, or one of four co-operating centres, will be assessed for the study. Those eligible and willing to take part will be randomly assigned to either medicine-first or laser-first.
The trial team is a group of ophthalmologists and researchers working at Moorfields Eye Hospital. The chief investigator is Professor Gus Gazzard and the trial team comprises Neil Nathwani (trial optometrist) and Amanda Davis (trial manager).
For more information about SLT and the LiGHT Study:
See the UCL website here
Find out more about SLT technology in the article “About Lumenisus and SLT”
The LiGHT Trial is discussed in an BBH (Building Better Healthcare) article here
If you’d like to know more about Professor Gazzard’s work on the SLT Trial, please don’t hesitate to get in touch here.